IV-SC Bridging: How Can MIDD Help
Includes a Live Web Event on 10/23/2024 at 12:00 PM (EDT)
-
You must log in to register
- Member - Free!
Overview of the 2024 MIDD Webinar Series
The 2024 MIDD Webinar Series, coordinated by Ana Ruiz and Sihem Bihorel, is a series of webinars focused on shaping the future of drug development and regulatory decision-making. Topics range from regulatory aspects from a European perspective to methods for dose selection in rare diseases. Topics range from regulatory aspects from a European perspective to methods for dose selection in rare diseases.
Anne Gaelle Dosne
Pharmacometrician
The Janssen Pharmaceutical Companies of Johnson & Johnson
Anne-Gaelle has been working as a pharmacometrician at J&J for 7 years. She has worked across many different therapeutic areas (including oncology, infections, and neuroscience) and across all clinical development phases. She has recently moved to leading the neuroscience PM subgroup. It is through one of her neuroscience projects that she was able to deep dive in an innovative application of IV-SC bridging based on pharmacodynamic endpoints, which was discussed within the FDA MIDD program as well as with other health authorities last year. This will be the topic we will be discussing today.
Outside of project work and her managerial role, Anne-Gaelle is also active in fostering reproducible PMX at her company. She also likes to be involved in methodological projects, which remind her fondly of her PhD time at Uppsala University.
Anne-Gaelle lives in Belgium with her husband and 2 young children.
Complete
Next
Failed
Available
Locked